| Literature DB >> 29078283 |
Dietmar Herndler-Brandstetter1, Liang Shan1, Yi Yao2, Carmen Stecher1, Valerie Plajer1, Melanie Lietzenmayer1, Till Strowig1, Marcel R de Zoete1, Noah W Palm1, Jie Chen1, Catherine A Blish3, Davor Frleta4, Cagan Gurer4, Lynn E Macdonald4, Andrew J Murphy4, George D Yancopoulos4, Ruth R Montgomery2, Richard A Flavell5,6.
Abstract
Immunodeficient mice reconstituted with a human immune system represent a promising tool for translational research as they may allow modeling and therapy of human diseases in vivo. However, insufficient development and function of human natural killer (NK) cells and T cell subsets limit the applicability of humanized mice for studying cancer biology and therapy. Here, we describe a human interleukin 15 (IL15) and human signal regulatory protein alpha (SIRPA) knock-in mouse on a Rag2-/- Il2rg-/- background (SRG-15). Transplantation of human hematopoietic stem and progenitor cells into SRG-15 mice dramatically improved the development and functional maturation of circulating and tissue-resident human NK and CD8+ T cells and promoted the development of tissue-resident innate lymphoid cell (ILC) subsets. Profiling of human NK cell subsets by mass cytometry revealed a highly similar expression pattern of killer inhibitory receptors and other candidate molecules in NK cell subpopulations between SRG-15 mice and humans. In contrast to nonobese diabetic severe combined immunodeficient Il2rg-/- (NSG) mice, human NK cells in SRG-15 mice did not require preactivation but infiltrated a Burkitt's lymphoma xenograft and efficiently inhibited tumor growth following treatment with the therapeutic antibody rituximab. Our humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and combinatory cancer immunotherapies and for studying how they elicit human antitumor immune responses in vivo. Published under the PNAS license.Entities:
Keywords: IL-15; ILC; NK cells; cancer immunotherapy; humanized mice
Mesh:
Substances:
Year: 2017 PMID: 29078283 PMCID: PMC5692533 DOI: 10.1073/pnas.1705301114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205